106 related articles for article (PubMed ID: 10071976)
1. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines.
Zamboni WC; Houghton PJ; Hulstein JL; Kirstein M; Walsh J; Cheshire PJ; Hanna SK; Danks MK; Stewart CF
Cancer Chemother Pharmacol; 1999; 43(4):269-76. PubMed ID: 10071976
[TBL] [Abstract][Full Text] [Related]
2. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
3. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
El-Gizawy SA; Hedaya MA
Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590
[TBL] [Abstract][Full Text] [Related]
4. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
[TBL] [Abstract][Full Text] [Related]
5. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
6. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
7. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.
Dickson PV; Hagedorn NL; Hamner JB; Fraga CH; Ng CY; Stewart CF; Davidoff AM
J Pediatr Surg; 2007 Jan; 42(1):160-5; discussion 165. PubMed ID: 17208558
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
11. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
12. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma.
Chen J; Balthasar JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):183-92. PubMed ID: 15664349
[TBL] [Abstract][Full Text] [Related]
13. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
14. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
15. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
16. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
17. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
18. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
[TBL] [Abstract][Full Text] [Related]
19. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
20. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
